GL1X · GenesisL1 explorer

Research workbench

Crystal structure of the bromodomain of human transcription activator BRG1 (SMARCA4) in complex with 2-(6-amino-5-(piperazin-1-yl) pyridazin-3-YL)PHENOL

Analyse Crystal structure of the bromodomain of human transcription activator BRG1… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6ZS2
Type
protein
Length
242 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Transcription activator BRG1
EC
3.6.4.-
UniProt
P51532
Ligands
FX5
Pockets
4 · best druggability 0.46

Structure

x-ray diffraction · 1 distinct chain · 60% helix, 2% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BTranscription activator BRG1 (EC 3.6.4.-)protein12160% helix, 2% strandP51532

Ligands and binding sites

  • FX5 · 2-(6-azanyl-5-piperazin-4-ium-1-yl-pyridazin-3-yl) phenol · ligand · 2 copies · chains A, B
  • EDO · 1,2-ethanediol · additive · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1620.460.8315FX5
2580.450.8315FX5
3970.340.7319empty
4560.250.7215empty

Interfaces

1 interface between chains.

  • A–B · 89 Ų buried · 2 hydrogen bonds · protein-protein

Compared structures

  • 6ZS2 · Crystal Structure of the bromodomain of human transcription activator BRG1 (SMARCA4) in… · the same entry in another collection · chain A against A, TM-score 1.00
  • P51532 · AlphaFold monomer V2.0 prediction for transcription activator BRG1 (P51532) · a predicted model of the same protein · chain A against A, TM-score 0.96

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.